title: Expression of MHC class I and class II antigens in pancreatic adenocarcinomas.
abstract: The antigens encoded by the major histocompatibility complex (MHC) are cell surface glycoproteins that play a fundamental role in the regulation of the immune response. Anomalous MHC expression in tumor cells has been viewed as an important feature to escape tumor recognition by immune cells. Low or absent MHC class I expression as well as ectopic MHC class II expression have been often observed to correlate with high grade malignancy and metastatic potential in a variety of human cancers. To date, very little investigation of MHC (HLA in man) class I and class II expression in human pancreatic cancer has been reported. We investigated this aspect on frozen sections of 8 pancreatic adenocarcinomas and 18 established in vitro cell lines. HLA class I was expressed in all but two cancers whereas de novo HLA class II expression was detected in 3 of 8 cancers. Interestingly, a hierarchy in the expression of the various subsets of HLA class II was found with HLA- DR > -DP > -DQ. Results on cell lines strongly resembled the ones obtained in cancer tissues. However, a peculiar feature was observed in certain cell lines. HLA class II antigens were expressed in only a few cell lines and in some of them a mixed population of positive and negative cells was found. Sorting and cloning of the two populations confirmed the existence of tumor cell clones with stable and distinct HLA class II phenotype. Taken together, these results indicate the cellular heterogeneity of pancreatic cancer cells with regard to the qualitative and quantitative expression of major histocompatibility complex genes, and may provide new insights for a better understanding of the tumorhost relationships in this extremely severe form of neoplasia.
authors.affiliation: Istituto di Immunologia e Malattie Infettive, Università di Verona, Italy.
authors.forename: M T
authors.initials: MT
authors.lastname: Scupoli
authors.forename: S
authors.initials: S
authors.lastname: Sartoris
authors.forename: G
authors.initials: G
authors.lastname: Tosi
authors.forename: M G
authors.initials: MG
authors.lastname: Ennas
authors.forename: M
authors.initials: M
authors.lastname: Nicolis
authors.forename: T
authors.initials: T
authors.lastname: Cestari
authors.forename: G
authors.initials: G
authors.lastname: Zamboni
authors.forename: G
authors.initials: G
authors.lastname: Martignoni
authors.forename: N R
authors.initials: NR
authors.lastname: Lemoine
authors.forename: A
authors.initials: A
authors.lastname: Scarpa
authors.forename: R S
authors.initials: RS
authors.lastname: Accolla
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology* / Q000473:pathology; D000328:Adult; D000368:Aged; D005260:Female; D015870:Gene Expression; D006682:HLA-DP Antigens / Q000235:genetics / Q000276:immunology*; D006683:HLA-DQ Antigens / Q000235:genetics / Q000276:immunology*; D006684:HLA-DR Antigens / Q000235:genetics / Q000276:immunology*; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000276:immunology* / Q000473:pathology; D014407:Tumor Cells, Cultured
chemical_list: D006682:HLA-DP Antigens; D006683:HLA-DQ Antigens; D006684:HLA-DR Antigens; D015395:Histocompatibility Antigens Class I; D007371:Interferon-gamma